Target Audience:
# Blood banks
# Pathologists and pathology laboratories
# Distributors of IVD products
# Research institutes
# Hospitals and clinics
# Healthcare institutions
# Group purchasing organizations (GPOs)
# Market research and consulting firms
The report "Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, Nursing Homes) - Global Forecast to 2023", The global hepatitis test solution/diagnosis market is expected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, at a CAGR of 4.9% during the forecast period (2018–2023).
Increasing number of blood transfusions & donations, high burden of hepatitis worldwide, benefits offered by point of care instruments & kits, and initiatives taken by government and non-government organizations are the major factors driving this market.
Research Methodology Used:
Top-down and bottom-up approaches were used to validate the size of the global hepatitis test solution/diagnosis market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary research, and their market revenues were determined through primary and secondary research.
Secondary sources include annual reports, press releases, and investor presentations of companies; white papers; medical journals; certified publications; articles from recognized authors; gold standard and silver standard websites; directories; and databases.
In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139802887
The hepatitis C segment is expected to grow at the highest rate in the next five years
On the basis of disease type, the market is segmented into hepatitis B, hepatitis C, and other hepatitis disease. The hepatitis C segment is projected to grow at the highest CAGR during the forecast period. This growth is primarily attributed to the increasing incidence of HCV infections and limited vaccination coverage.
The ELISA segment is expected to hold the largest market share during the forecast period
On the basis of technology, the hepatitis test solution/diagnosis market is segmented into ELISA, rapid diagnostics test, PCR, INAAT, and other technologies. In 2018, the ELISA is expected to account for the largest market share, by technology. The wide acceptance of this test in clinical practices to diagnose hepatitis is the main factor driving this market.
North America is expected to dominate the hepatitis test solution/diagnosis market in 2018
North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market in 2018. The large share of the North America region is primarily attributed to factors such as the rising adoption of advanced technologies, developed healthcare systems in the US and Canada, and the presence of a large number of leading national clinical laboratories.
The APAC region is expected to grow at the highest CAGR over the next five years. The growth of the hepatitis test solution/diagnosis market in this region is driven by the modernization of healthcare infrastructure, high burden of hepatitis infections, increased healthcare spending by a larger population base, and the rising penetration of cutting-edge clinical laboratory technologies.
The key players operating in this market include Abbott Laboratories (US), Roche (Switzerland), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), bioMérieux (France), Danaher (US), and Grifols (Spain).
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=139802887
Collaborations, agreements, and partnerships remain at the center of the strategic growth initiatives adopted by most of the key players in the global hepatitis test solution/diagnosis market. Companies such as Abbott Laboratories, Roche Diagnostics, Bio-Rad, DiaSorin, Danaher, and Grifols have been focusing on this inorganic strategy to enhance their market presence. Players also adopted product launches, product approval, and acquisition as growth strategies.
Global Hepatitis Test Solution Diagnosis Market Research Report: Information by Disease Type (Hepatitis A, Hepatitis B, Hepatitis C and others), Type of Technology [Nucleic Acid Testing (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests (RDT), Chemiluminescence Immunoassay (CLIA), Genotyping and others], End User (Hospitals, Clinics, Diagnostic Laboratories, Blood Banks, Research Institutes and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027Market SnapshotThe global market for hepatitis test solution/diagnosis can expect to attain a CAGR of 4.9% during the forecast period (2018-2023), Market Research Future (MRFR) reveals.Market Drivers and Main BarriersHepatitis testing helps in determining the genotype of hepatitis that triggers the ailment.
The test also helps understand the method of treatment ideal for the patient.
These factors accelerate product demand in the market to a great extent.The global market for hepatitis test solution and diagnosis could expect strong growth in the subsequent years as a result of the surge in cases of viral hepatitis as well as autoimmune diseases Increasing healthcare spending is another critical factor that could work in favor of the market in the near future.Throughout the assessment period, demand from China, South Korea, Turkey, India, Brazil, and South Africa is most likely to accelerate.
Additional factors promoting market growth include surging medical tourism, coupled with the presence of a huge number of undiagnosed cases.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/7481 Market SegmentationThe worldwide market for hepatitis test solution/diagnosis has been segmented on the basis of disease type, technology, end-user, and region.Depending on the disease type, the market is segmented into Hepatitis A, Hepatitis B, Hepatitis C, and others.The global hepatitis test solution/diagnosis market, with respect to the technology, is considered for enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT) and others.The various end-users in the market are hospital & diagnostic laboratories, blood banks, and others.Regional InsightEurope, Middle East & Africa, Asia Pacific, and the Americas are the primary markets for hepatitis test solution/diagnosis.The Americas is touted to be the leading hepatitis test solution/diagnosis market in the coming years.
The rise in bacterial infection and adoption of clinical practices for a variety of disease treatment result in the superlative growth of the regional market.
The Centers for Disease Control and Prevention (CDC) reveals that in 2016, almost 2,967 cases of acute hepatitis C infection were estimated in the United States (US).
Market HighlightsThe global hepatitis test solution/diagnosis market is expected to grow at an approximate CAGR of 4.9% during forecast period, 2018–2023.Hepatitis is a liver infection caused by the hepatitis virus and results to cause liver inflammation, or sometimes liver damage.
This pathological infection spreads through contaminated blood, infected medical devices and lasts for several years.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/7481According to the World Health Organization (WHO) 2018 fact sheet, it was estimated that 71 million population across the globe have chronic hepatitis C and it was also mentioned that approximately 399,000 number of people die each year from hepatitis infection.
Such a large population affected by hepatitis infection boosts the market growth.However, the factors such as side effects associated with the medications and treatment are expected to hinder the market growth.SegmentationThe global hepatitis test solution diagnosis market is segmented on the basis of disease type, technology, end user and region.On the basis of disease type, the market is segmented into Hepatitis A, Hepatitis B, Hepatitis C and others.The global hepatitis test solution/diagnosis market by technology is segmented into enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT) and others.On the basis of end-user, the market is categorized into hospital & diagnostic laboratories, blood banks and other.Regional AnalysisThe Americas dominates the global market for hepatitis test solution/diagnosis owing to the increasing awareness about hepatitis infection and various symptoms associated to it, rising geriatric population, and presence of major market players within the region.
Additionally, the rising economy and high expenditure on healthcare sector within the region fuels the market growth during the forecast period.
In 2017, it was estimated that Europe stood second in the global hepatitis test solution/diagnosis market due to increasing prevalence of hepatitis infection, kidney problem and other infectious diseases within the region.
Asia Pacific was the fastest growing region for the global hepatitis test solution/diagnosis market in 2017.
Global Hepatitis Test Solution Diagnosis Market Research Report: Information by Disease Type (Hepatitis A, Hepatitis B, Hepatitis C and others), Type of Technology [Nucleic Acid Testing (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests (RDT), Chemiluminescence Immunoassay (CLIA), Genotyping and others], End User (Hospitals, Clinics, Diagnostic Laboratories, Blood Banks, Research Institutes and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025Market HighlightsThe global hepatitis test solution/diagnosis market is expected to grow at an approximate CAGR of 4.9% during forecast period, 2018–2023.Hepatitis is a liver infection caused by the hepatitis virus and results to cause liver inflammation, or sometimes liver damage.
There is different type of hepatitis infection such as hepatitis A, hepatitis B, and hepatitis C which cause this infection.
This pathological infection spreads through contaminated blood, infected medical devices and lasts for several years.Intended AudiencePharmaceutical companiesGovernment and private laboratoriesResearch and development (R) companiesResearch laboratoriesMarket research and consulting service providersAvail a Free Sample@ https://www.medgadget.com/2020/07/hepatitis-test-solution-diagnosis-market-technology-trends-2020-global-size-growth-factors-demand-report-covid19-impact-comprehensive-analysis-and-forecast-to-2025.html The patient suffering from hepatitis infection faces many symptoms such as poor appetite, weakness, weight loss, itching on skin, jaundice, dark-coloured urine, swelling on legs, drowsiness and many more.
The key factors responsible to drive the market are rising awareness regarding the disease, growing adoption of innovative technologies, and increasing health care expenditure.
According to the World Health Organization (WHO) 2018 fact sheet, it was estimated that 71 million population across the globe have chronic hepatitis C and it was also mentioned that approximately 399,000 number of people die each year from hepatitis infection.
Such a large population affected by hepatitis infection boosts the market growth.However, the factors such as side effects associated with the medications and treatment are expected to hinder the market growth.SegmentationThe global hepatitis test solution/diagnosis market is segmented on the basis of disease type, technology, end user and region.On the basis of disease type, the market is segmented into Hepatitis A, Hepatitis B, Hepatitis C and others.The global hepatitis test solution/diagnosis market by technology is segmented into enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT) and others.On the basis of end-user, the market is categorized into hospital & diagnostic laboratories, blood banks and other.Regional AnalysisThe Americas dominates the global market for hepatitis test solution/diagnosis owing to the increasing awareness about hepatitis infection and various symptoms associated to it, rising geriatric population, and presence of major market players within the region.
Because different types of hepatitis viruses can cause similar symptoms, it is very important that a series of diagnostic test is run to identify the virus thus the true cause of the disease.
Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=54960The global hepatitis test solution and diagnosis market is already a multi-billion dollar industry and is expected to remain strong between 2018 and 2026.
Transparency Market Research (TMR) forecasts the market to exhibit growth at a steady pace through the course of the forecast period.
The rising incidence of hepatitis diseases will create growth opportunities for the market in the coming years.
Factors such as the rising incidence of viral hepatitis and autoimmune diseases are likely fuel the demand for hepatitis test solutions and diagnosis.
Therefore, the rising prospects across emerging nations are likely to favor the expansion of the hepatitis test solutions and diagnosis market.
